Tags

Type your tag names separated by a space and hit enter

Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients.
Clin Endocrinol (Oxf). 2006 Apr; 64(4):469-73.CE

Abstract

OBJECTIVES

The aims of this study were to investigate if (i) urinary concentrations of activin A and inhibin A are altered in pre-eclampsia (PE) and (ii) to study the relationship between uterine vein and peripheral vein concentrations of these hormones in PE patients.

DESIGN AND METHOD

In a retrospective study, maternal peripheral vein and uterine vein serum and maternal urine samples collected at the time of delivery were analysed. There were three groups of patients; (i) group 1: term normal pregnancies (n = 19) (ii) group 2: patients who developed PE < or = 37 weeks (n = 17) and (iii) group 3: patients who developed PE 37-40 weeks (n = 8). Serum and urinary activin A, follistatin, inhibin A and pro alpha C and urinary creatinine levels were measured using enzyme immunoassays in the laboratory.

RESULTS

Normal pregnant urine samples had very low levels of activin A and inhibin A. Both groups 2 and 3 PE patients had significantly higher levels of inhibin A (P < 0.001) and activin A (P < 0.001) compared to the controls. Pro-alpha C was not altered and follistatin was below the detection limit of the assay in the urine. Maternal peripheral serum activin A and inhibin A were significantly higher in groups 2 (P < 0.001) and 3 (P < 0.05) patients compared to the controls. Pro-alpha C-containing inhibins were higher in group 2 patients (P < 0.05) compared to the controls in the peripheral circulation. Uterine vein serum activin A and inhibin A levels were also significantly higher in groups 2 (P < 0.001) and 3 (P < 0.05) patients compared to the controls. There was a highly significant positive correlation between peripheral and uterine vein serum concentrations of activin A, follistatin, inhibin A and pro alpha C, suggesting the same source for these proteins in PE.

CONCLUSION

Urinary activin A and inhibin A are raised in groups 2 and 3 PE patients. The magnitude of rise (> 25-fold) suggests these proteins may rise in patients before the onset of the clinical symptoms of PE. Uterine vein levels of these proteins are also raised in PE.

Authors+Show Affiliations

Department of Obstetrics and Gynaecology, Royal Free University College Medical School, London, UK. s.muttukrishna@ucl.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16584522

Citation

Muttukrishna, S, et al. "Uterine Vein and Maternal Urinary Levels of Activin a and Inhibin a in Pre-eclampsia Patients." Clinical Endocrinology, vol. 64, no. 4, 2006, pp. 469-73.
Muttukrishna S, Hyett J, Paine M, et al. Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients. Clin Endocrinol (Oxf). 2006;64(4):469-73.
Muttukrishna, S., Hyett, J., Paine, M., Moodley, J., Groome, N., & Rodeck, C. (2006). Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients. Clinical Endocrinology, 64(4), 469-73.
Muttukrishna S, et al. Uterine Vein and Maternal Urinary Levels of Activin a and Inhibin a in Pre-eclampsia Patients. Clin Endocrinol (Oxf). 2006;64(4):469-73. PubMed PMID: 16584522.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients. AU - Muttukrishna,S, AU - Hyett,J, AU - Paine,M, AU - Moodley,J, AU - Groome,N, AU - Rodeck,C, PY - 2006/4/6/pubmed PY - 2006/7/25/medline PY - 2006/4/6/entrez SP - 469 EP - 73 JF - Clinical endocrinology JO - Clin. Endocrinol. (Oxf) VL - 64 IS - 4 N2 - OBJECTIVES: The aims of this study were to investigate if (i) urinary concentrations of activin A and inhibin A are altered in pre-eclampsia (PE) and (ii) to study the relationship between uterine vein and peripheral vein concentrations of these hormones in PE patients. DESIGN AND METHOD: In a retrospective study, maternal peripheral vein and uterine vein serum and maternal urine samples collected at the time of delivery were analysed. There were three groups of patients; (i) group 1: term normal pregnancies (n = 19) (ii) group 2: patients who developed PE < or = 37 weeks (n = 17) and (iii) group 3: patients who developed PE 37-40 weeks (n = 8). Serum and urinary activin A, follistatin, inhibin A and pro alpha C and urinary creatinine levels were measured using enzyme immunoassays in the laboratory. RESULTS: Normal pregnant urine samples had very low levels of activin A and inhibin A. Both groups 2 and 3 PE patients had significantly higher levels of inhibin A (P < 0.001) and activin A (P < 0.001) compared to the controls. Pro-alpha C was not altered and follistatin was below the detection limit of the assay in the urine. Maternal peripheral serum activin A and inhibin A were significantly higher in groups 2 (P < 0.001) and 3 (P < 0.05) patients compared to the controls. Pro-alpha C-containing inhibins were higher in group 2 patients (P < 0.05) compared to the controls in the peripheral circulation. Uterine vein serum activin A and inhibin A levels were also significantly higher in groups 2 (P < 0.001) and 3 (P < 0.05) patients compared to the controls. There was a highly significant positive correlation between peripheral and uterine vein serum concentrations of activin A, follistatin, inhibin A and pro alpha C, suggesting the same source for these proteins in PE. CONCLUSION: Urinary activin A and inhibin A are raised in groups 2 and 3 PE patients. The magnitude of rise (> 25-fold) suggests these proteins may rise in patients before the onset of the clinical symptoms of PE. Uterine vein levels of these proteins are also raised in PE. SN - 0300-0664 UR - https://www.unboundmedicine.com/medline/citation/16584522/Uterine_vein_and_maternal_urinary_levels_of_activin_A_and_inhibin_A_in_pre_eclampsia_patients_ L2 - https://doi.org/10.1111/j.1365-2265.2006.02476.x DB - PRIME DP - Unbound Medicine ER -